The Next Winner in the Plant-Based Boom is Here
Co-founder left Silicon Valley job to create the next game-changing plant-based company.
Continue Reading

ARDS Insider Trading (Aridis Pharmaceuticals)

Insider Ownership Percentage: 18.10%
Insider Buying (Last 12 Months): $35,290.00
Insider Selling (Last 12 Months): $0.00

Aridis Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Aridis Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aridis Pharmaceuticals Share Price & Price History

Current Price: $2.39
Price Change: Price Increase of +0.08 (3.46%)
As of 11/26/2021 01:00 AM ET

This chart shows the closing price history over time for ARDS up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Crypto's next trillion-dollar coin.
He recommended Bitcoin at $428, the first trillion-dollar coin. Now he's recommending a new crypto.
Learn more

Aridis Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
7/27/2021John F. HamiltonDirectorBuy2,000$4.87$9,740.00702,132View SEC Filing Icon  
7/27/2021Vu TruongCEOBuy5,000$5.11$25,550.00View SEC Filing Icon  
See Full Table
Insider Selling at Aridis Pharmaceuticals?
Sign-up to receive InsiderTrades.com's daily insider buying and selling report for Aridis Pharmaceuticals and related companies.

SEC Filings (Institutional Ownership Changes) for Aridis Pharmaceuticals (NASDAQ:ARDS)

16.20% of Aridis Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at ARDS by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Aridis Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
11/16/2021Millennium Management LLC74,559$0.27M0.0%N/A0.615%Search for SEC Filing on Google Icon
11/12/2021Geode Capital Management LLC35,899$0.13M0.0%N/A0.296%Search for SEC Filing on Google Icon
11/12/2021AIGH Capital Management LLC150,591$0.55M0.1%-67.2%1.243%Search for SEC Filing on Google Icon
11/9/2021BlackRock Inc.42,227$0.16M0.0%+33.6%0.348%Search for SEC Filing on Google Icon
11/9/2021Wealth Architects LLC14,077$52K0.0%N/A0.116%Search for SEC Filing on Google Icon
8/13/2021Vanguard Group Inc.159,946$1.18M0.0%+6.9%1.424%Search for SEC Filing on Google Icon
8/12/2021AIGH Capital Management LLC459,261$3.33M0.6%+8.5%4.088%Search for SEC Filing on Google Icon
7/19/2021Minot Wealth Management LLC25,000$0.15M0.0%-65.4%0.223%Search for SEC Filing on Google Icon
5/19/2021Worth Venture Partners LLC105,413$0.62M0.3%+19.9%0.938%Search for SEC Filing on Google Icon
5/18/2021Perritt Capital Management Inc.10,100$60K0.0%N/A0.090%Search for SEC Filing on Google Icon
5/7/2021BlackRock Inc.26,381$0.16M0.0%+11.4%0.296%Search for SEC Filing on Google Icon
4/29/2021Minot Wealth Management LLC72,230$0.43M0.1%-45.4%0.643%Search for SEC Filing on Google Icon
2/17/2021Worth Venture Partners LLC87,932$0.53M0.4%N/A0.874%Search for SEC Filing on Google Icon
1/28/2021Minot Wealth Management LLC132,283$0.80M0.2%N/A1.314%Search for SEC Filing on Google Icon
11/6/2020BlackRock Inc.22,600$0.16M0.0%+15.1%0.253%Search for SEC Filing on Google Icon
11/27/2019Millennium Management LLC25,569$0.17M0.0%N/A0.287%Search for SEC Filing on Google Icon
8/14/2019Vanguard Group Inc.43,281$0.44M0.0%-5.2%0.534%Search for SEC Filing on Google Icon
2/15/2019Millennium Management LLC12,112$0.13M0.0%-48.6%0.149%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Aridis Pharmaceuticals logo
Aridis Pharmaceuticals, Inc. engages in the discovery and development of targeted immunotherapy using fully human monoclonal antibodies, or mAbs, to treat life-threatening infections. Its products include AR-301, AR-101, AR-501, AR-712, AR-701, AR-401, AR-105 and AR-201. The company was founded by Eric J. Patzer and Vu L. Truong in 2003 and is headquartered in Los Gatos, CA.
Read More on Aridis Pharmaceuticals

Today's Range

Now: $2.39
Low: $2.27
High: $2.49

50 Day Range

MA: $3.28
Low: $2.18
High: $4.02

52 Week Range

Now: $2.39
Low: $2.15
High: $8.47

Volume

70,700 shs

Average Volume

66,494 shs

Market Capitalization

$33.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.12

Who are the company insiders with the largest holdings of Aridis Pharmaceuticals?

Aridis Pharmaceuticals' top insider shareholders include:
  1. John F Hamilton (Director)
  2. Vu Truong (CEO)

Who are the major institutional investors of Aridis Pharmaceuticals?

Aridis Pharmaceuticals' top institutional investors include:
  1. AIGH Capital Management LLC — 1.24%
  2. Millennium Management LLC — 0.62%
  3. BlackRock Inc. — 0.35%
  4. Geode Capital Management LLC — 0.30%
  5. Wealth Architects LLC — 0.12%

Which major investors are selling Aridis Pharmaceuticals stock?

During the last quarter, ARDS stock was sold by these institutional investors:
  1. AIGH Capital Management LLC

Which major investors are buying Aridis Pharmaceuticals stock?

During the last quarter, ARDS stock was bought by institutional investors including:
  1. Millennium Management LLC
  2. Geode Capital Management LLC
  3. Wealth Architects LLC
  4. BlackRock Inc.
Within the last year, these company insiders have bought Aridis Pharmaceuticals stock:
  1. John F Hamilton (Director)
  2. Vu Truong (CEO)
The Next Winner in the Plant-Based Boom is Here
Co-founder left Silicon Valley job to create the next game-changing plant-based company.
Continue Reading